免疫捕获结合LC-MS/MS定量分析生长激素20与22 kDa亚型及其在垂体腺瘤中的临床评价
本研究建立了免疫捕获结合液相色谱-串联质谱(LC-MS/MS)法,可同时定量生长激素1(GH1)的20和22 kDa亚型,灵敏度、准确度、精密度和线性均经过评估。在63例垂体生长激素腺瘤患者中,80.0%(51/63)患者22/20 kDa GH1比值升高,6例临床特征和内分泌预后不佳者20 kDa GH1水平升高。该方法无需酶解,可能有助于改善GH相关疾病的生化缓解评估和预后分层。
要点
- 免疫捕获LC-MS/MS可同时定量20和22 kDa GH1亚型,无需酶解。
- 22/20 kDa GH1比值在多数垂体腺瘤患者中升高,20 kDa升高与不良临床特征相关。
- LC-MS/MS测总GH1低于免疫法但强相关(r=0.991, p<0.01)。
核心结论
- 免疫捕获LC-MS/MS法可同时定量20和22 kDa GH1亚型,无需酶解。
- 该方法可能改善GH相关疾病的生化缓解评估和预后分层。
研究设计与样本
- 研究开发了免疫捕获结合LC-MS/MS法,使用抗体包被磁珠从1 mL血清中分离GH1,稳定同位素标记22 kDa GH1作为内标。
- 评估了灵敏度、准确度、精密度和线性,并在63例垂体生长激素腺瘤患者中分析血清GH1亚型。
主要发现
- 线性动态范围:20 kDa GH1为0.2-20.0 μg/L,22 kDa GH1为1.0-100.0 μg/L。
- 批内和批间变异系数<10%,内标校正后回收率95.0-102.5%。
- LC-MS/MS测总GH1系统性低于免疫法,但两法强相关(r=0.991, p<0.01)。
- 80.0%(51/63)垂体腺瘤患者22/20 kDa GH1比值升高,6例临床特征和内分泌预后不佳者20 kDa GH1水平升高。
临床怎么用
- 该法可用于同时定量20和22 kDa GH1亚型,无需酶解,可能辅助GH相关疾病的生化缓解评估和预后分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The 20- and 22-kDa isoforms of growth hormone 1 (GH1) play potentially distinct physiological and pathological roles, but their structural similarity makes quantification challenging. Conventional immunoassays lack sufficient specificity, highlighting the need for more precise analytical methods. METHODS: We developed a method combining immunocapture with liquid chromatography-tandem mass spectrometry (LC-MS/MS) for precise quantification of GH1 isoforms, with evaluation of sensitivity, accuracy, precision, and linearity. GH1 was isolated from 1-mL serum samples by immunocapture using antibody-coated magnetic beads, eluted, and quantified by LC-MS/MS. Stable isotope-labeled 22-kDa GH1 was used as an internal standard (IS). Clinical applicability was evaluated by analyzing serum GH1 isoforms in 63 patients with somatotroph adenoma. RESULTS: The assay demonstrated linear dynamic ranges of 0.2-20.0 μg/L for 20-kDa GH1 and 1.0-100.0 μg/L for 22-kDa GH1. Intra- and inter-assay coefficients of variation were <10 %, and recoveries ranged from 95.0 to 102.5 % after IS correction. Although total GH1 concentrations measured by LC-MS/MS were systematically lower than those obtained by immunoassay, the two methods were strongly correlated (r=0.991, p<0.01). Most patients with somatotroph adenoma (80.0 %; 51/63) exhibited increased 22/20-kDa GH1 ratios, while six patients with unfavorable clinical features and endocrine prognosis exhibited elevated 20-kDa GH1 levels. CONCLUSIONS: This immunocapture LC-MS/MS method enables simultaneous quantification of 20- and 22-kDa GH1 isoforms without enzymatic digestion. The implementation of this method may refine the assessment of biochemical remission and prognostic stratification in GH-related disorders.
引用
- Hu Y, Chen Y, Xia Q, et al. Quantitative analysis and clinical evaluation of 20- and 22-kDa growth hormone isoforms in somatotroph adenoma using immunocapture coupled with LC-MS/MS. Clin Chem Lab Med. 2026. PMID: 42154802. doi:10.1515/cclm-2026-0382
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。